GLP-1 Receptor Agonists Reduce Cardiovascular Events Post-MI and Stroke in T2D

Overview

This nationwide Czech registry study found that initiation of GLP-1 receptor agonists (GLP-1RA) within 12 months after myocardial infarction (MI) or ischemic stroke in patients with Type 2 diabetes (T2D) was associated with a 30% reduction in major adverse cardiovascular events (MACE) and a 40–45% reduction in all-cause and cardiovascular mortality. Despite these benefits, GLP-1RA use remained low, particularly among women and older adults.

Background

Cardiovascular disease is the leading cause of death in patients with Type 2 diabetes, with MI and ischemic stroke contributing significantly to morbidity and mortality. GLP-1 receptor agonists have demonstrated cardiovascular benefits in randomized trials, reducing MACE and mortality beyond glucose lowering effects. International guidelines recommend GLP-1RA for patients with T2D and established atherosclerotic cardiovascular disease. However, real-world data on their effectiveness and uptake in high-risk post-MI and post-stroke populations have been limited.

Data Highlights

Key Findings

• GLP-1RA therapy initiated within 12 months post-MI or stroke was associated with a 30% lower risk of major adverse cardiovascular events (MACE).
• Use of GLP-1RA was linked to a 39–41% reduction in all-cause mortality among T2D patients post-MI or stroke.
• Cardiovascular mortality risk was reduced by approximately 45% in GLP-1RA users compared to non-users.
• Despite demonstrated benefits, only about 2% of eligible MI and stroke survivors with T2D were prescribed GLP-1RA therapy.
• Significant disparities in GLP-1RA use were observed, with lower uptake among women and older adults.
• The study utilized comprehensive nationwide registry data with robust propensity score matching and long median follow-up periods (27–35 months).

Clinical Implications

GLP-1 receptor agonists should be considered as a key component of secondary prevention in patients with Type 2 diabetes following myocardial infarction or ischemic stroke due to their significant cardiovascular and mortality benefits. Clinicians should address the current underutilization and disparities in prescribing, particularly focusing on improving access for women and older patients to optimize outcomes. Incorporating GLP-1RA therapy aligns with guideline recommendations and real-world evidence supporting their cardioprotective effects.

Conclusion

In real-world clinical practice, GLP-1 receptor agonist therapy after MI or ischemic stroke in patients with Type 2 diabetes substantially reduces the risk of recurrent cardiovascular events and death. Efforts are needed to increase equitable use of these agents to improve secondary prevention outcomes.

References

1. Czech Nationwide Registry Study 2015–2024 -- Efficacy of GLP-1 Receptor Agonists in Preventing Cardiovascular Events Post-MI and Stroke